FindTrial
Sign In

Clinical outcomes and influence factors analysis on maternal using nucleos(t)die antiviral agents for preventing mother-to-child transmission during the second and third trimesters

Clinical outcomes and influence factors analysis on maternal using nucleos(t)die antiviral agents for preventing mother-to-child transmission during the second and third trimesters

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OON-16009716
Enrollment
Unknown
Registered
2016-11-02
Start date
2016-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Hepatitis B Virus

Interventions

1:Anti virus treatment

Sponsors

Beijing Ditan Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
23 Years to 45 Years

Inclusion criteria

Inclusion criteria: 1. The time of positive HBsAg longer than 6 months; 2. HBV-DNA >106 IU/ml; 3. Normal pregnancy; 4. Aged 23 to 45 years; 5. Normal liver enzyme level or less than 2 ULN; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Activity hepatitis; 2. Has been treated by anti-virus or has a history of anti-virus; 3. Complicated with HAV, HCV, HDV, HEV or other liver diseases and HIV; 4. Using steroid hormones and immunosuppressive agents; 5. Presenting threatened abortion symptom or treatment for early pregnancy complication; 6. Other condition considered not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
ALT;serum biochemical test;safety;the level of HBV DNA;serum marker for hepatitis B;—

Countries

China

Contacts

Public ContactHuichun Xing

Beijing Ditan Hospital, Capital Medical University

huichunxing@126.com+86 010 84322291

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026